Bessemer Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $35K | Sell |
116
-6
| -5% | -$1.81K | ﹤0.01% | 1803 |
|
|
2026
Q1 | $40K | Sell |
122
-105
| -46% | -$35.7K | ﹤0.01% | 1734 |
|
|
2025
Q4 | $90K | Buy |
227
+5
| +2% | +$2.21K | ﹤0.01% | 1503 |
|
|
2025
Q3 | $101K | Buy |
222
+30
| +16% | +$12.2K | ﹤0.01% | 1279 |
|
|
2025
Q2 | $63K | Buy |
192
+84
| +78% | +$23.2K | ﹤0.01% | 1284 |
|
|
2025
Q1 | $29K | Buy |
108
+69
| +177% | +$17.7K | ﹤0.01% | 1413 |
|
|
2024
Q4 | $9K | Buy |
39
+6
| +18% | +$1.58K | ﹤0.01% | 1788 |
|
|
2024
Q3 | $9K | Buy |
+33
| New | +$8.59K | ﹤0.01% | 1694 |
|
|
2023
Q4 | – | Sell |
-476
| Closed | -$84K | – | 2128 |
|
|
2023
Q3 | $84K | Buy |
476
+105
| +28% | +$20K | ﹤0.01% | 1243 |
|
|
2023
Q2 | $70K | Buy |
+371
| New | +$73.6K | ﹤0.01% | 1314 |
|
|
2022
Q4 | – | Sell |
-84,280
| Closed | -$16.9M | – | 1854 |
|
|
2022
Q3 | $16.9M | Buy |
84,280
+84,256
| +351,067% | +$16.1M | 0.04% | 208 |
|
|
2022
Q2 | $4K | Buy |
+24
| New | +$3.4K | ﹤0.01% | 1561 |
|
|
2021
Q4 | – | Sell |
-39
| Closed | -$7K | – | 1845 |
|
|
2021
Q3 | $7K | Buy |
+39
| New | +$7.32K | ﹤0.01% | 1441 |
|
|
2021
Q2 | – | Sell |
-771
| Closed | -$109K | – | 1567 |
|
|
2021
Q1 | $109K | Buy |
771
+63
| +9% | +$9.48K | ﹤0.01% | 870 |
|
|
2020
Q4 | $92K | Sell |
708
-300
| -30% | -$40.1K | ﹤0.01% | 878 |
|
|
2020
Q3 | $147K | Sell |
1,008
-200
| -17% | -$28.4K | ﹤0.01% | 778 |
|
|
2020
Q2 | $179K | Buy |
+1,208
| New | +$163K | ﹤0.01% | 1157 |
|
|
2019
Q2 | – | Sell |
-50
| Closed | -$5K | – | 1629 |
|
|
2019
Q1 | $5K | Sell |
50
-33
| -40% | -$2.76K | ﹤0.01% | 1587 |
|
|
2018
Q4 | $6K | Buy |
+83
| New | +$6.38K | ﹤0.01% | 1732 |
|
|
2017
Q4 | – | Sell |
-175
| Closed | -$21K | – | 1679 |
|
|
2017
Q3 | $21K | Hold |
175
| – | – | ﹤0.01% | 1476 |
|
|
2017
Q2 | $14K | Buy |
+175
| New | +$11.2K | ﹤0.01% | 1533 |
|
|
2016
Q3 | – | Sell |
-55
| Closed | -$3K | – | 1792 |
|
|
2016
Q2 | $3K | Hold |
55
| – | – | ﹤0.01% | 1216 |
|
|
2016
Q1 | $3K | Sell |
55
-490
| -90% | -$32.6K | ﹤0.01% | 1315 |
|
|
2015
Q4 | $51K | Sell |
545
-28
| -5% | -$2.6K | ﹤0.01% | 956 |
|
|
2015
Q3 | $46K | Buy |
573
+518
| +942% | +$57.6K | ﹤0.01% | 965 |
|
|
2015
Q2 | $7K | Sell |
55
-490
| -90% | -$58.6K | ﹤0.01% | 1295 |
|
|
2015
Q1 | $57K | Buy |
545
+490
| +891% | +$49.7K | ﹤0.01% | 947 |
|
|
2014
Q4 | $5K | Buy |
+55
| New | +$5.1K | ﹤0.01% | 1360 |
|
Other funds holding ALNY
Bessemer Group's ALNY Position: Q2 2026 in Review
Bessemer Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 4.9% in Q2 2026, selling an estimated $1.81K and leaving 116 shares worth $35K. The position accounts for ﹤0.01% of the portfolio, ranked #1803.
Bessemer Group first reported a position in ALNY in Q4 2014 and has held it in 28 quarters since. The position peaked at $16.9M in Q3 2022. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Bessemer Group held 116 shares of Alnylam Pharmaceuticals worth $35K as of Q2 2026.
- Bessemer Group sold 6 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.81K.
- Alnylam Pharmaceuticals made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #1803 holding.
- Bessemer Group first reported a position in Alnylam Pharmaceuticals in Q4 2014 and has held it in 28 quarters since.
- Bessemer Group's Alnylam Pharmaceuticals position peaked at $16.9M in Q3 2022.
- 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.